CBIO

Crescent BiopharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

Crescent has a funded oncology pipeline, ASCEND is already underway, CR-002 is targeting an IND in mid-2026, and management says cash should fund operations into 2028 after the $185 million private placement, giving it a real window to reach several clinical inflection points [#PR-2026-02-26].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -12.1.

What can break

Cash runway is stated into 2028, but sustained high R&D burn and a pre-revenue model still leave financing risk if timelines slip.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $18.00 · Bull $30.00 · Bear $10.00

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $29.29

Why

Momentum75 · Δ7d -12.1

Value41 · Δ7d +0.1

Sentiment58 · Δ7d +7.7

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-12.1

Δ21d

-19.8

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+7.7

Δ21d

+1.5

Why this grade

Composite grade B. Momentum 74.8 / Value 41.1 / Sentiment 58.3

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$543.72M

Beta

1.34

Shares Out

13.89M

P/E (TTM) · Derived

-2.6

P/S (TTM)

P/FCF (TTM) · Derived

-4.31

Rev YoY

-100.0%

EPS YoY

+90.2%

Gross Margin

Op Margin

-422973.5%

Net Debt

-$10.72M

Current Ratio

6.63

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology